MiStent is a drug-eluting stent in the early stages of development at Micell that is being designed to allow precise control of both drug release and pharmacokinetics. Micell's proprietary surface modification technology provides a unique drug delivery system through the use of bioabsorbable polymers. The company's rapid-absorbing drug/polymer formulation is intended to precisely and consistently control drug elution and the duration of polymer exposure. As a result, Micell's coating is intended to deliver a precise therapeutic solution for coronary artery disease with the potential to avoid the long-term safety concerns associated with current drug-eluting stents.

Using an approved drug (sirolimus) and polymer, Micell's patented supercritical fluid technology allows a carefully controlled drug/polymer coating to be applied a bare metal stent. In pre-clinical trials, the drug completely elutes and most of the polymer degrades within 45-90 days in vivo - resulting in a bare metal stent. This early data suggests that this solvent-free coating process may have the potential to reduce both the incidence of late-stent thrombosis associated with current drug-eluting stents and patient dependence on anti-platelet drug treatment.*

With a goal of combining the efficacy of drug-eluting stents with the long-term safety of bare-metal stents, the choice of the bare-metal stent at the core of the combination product was critical. In a strategic agreement with Maxcor Lifescience, Inc., Micell is leveraging the strengths of Maxcor's Genius MAGIC Cobalt Chromium Coronary Stent System - a state-of-the-art bare-metal stent shown to demonstrate excellent deliverability, conformability and flexibility.

* based on animal data. Clinical significance in humans is unknown.

Caution: The Micell products described on this website are not available for sale or clinical use for any indications.